The role of extended prostate biopsy on prostate cancer detection rate: a study performed on the bench

Nesrallah, Luciano J.; Nesrallah, Adriano; Antunes, Alberto A.; Leite, Kátia Ramos Moreira; Srougi, Miguel

doi:10.1590/s1677-55382008000500004

Cited by 13 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The better performance of extended biopsy when compared to fewer samplings schemes can be exemplified by the Nesrallah's study, who found PC detection rates of 75% and 88% when 6 or 14 cores were respectively sampled (12). However, our undergrading rate was considered significant even when employing extended biopsy.…”

Section: Commentsmentioning

confidence: 70%

Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy

et al. 2010

Self Cite

View full text Add to dashboard Cite

Purpose: The aim of our study is to evaluate the undergrading and understaging rates in patients with clinically localized insignificant prostate cancer who underwent radical prostatectomy. Materials and Methods: Between July 2005 and July 2008, 406 patients underwent radical prostatectomy for clinical localized prostate cancer in our hospital. Based on preoperative data, 93 of these patients fulfilled our criteria of non-significance: Gleason score < 7, stage T1c, PSA < 10 ng/mL and percentage of affected fragments less than 25%. The pathologic stage and Gleason score were compared to preoperative data to evaluate the rate of understaging and undergrading. The biochemical recurrence free survival of these operated insignificant cancers were also evaluated. Results: On surgical specimen analysis 74.7% of patients had Gleason score of 6 or less and 25.3% had Gleason 7 or greater. Furthermore 8.3% of cases showed extracapsular extension. After 36 months of follow-up 3.4% had biochemical recurrence, defined by a PSA above 0.4 ng/mL. Conclusions: Despite the limited number of cases, we have found considerable rates of undergrading and understaging in patients with prostate cancer whose current definitions classified them as candidates for active surveillance. According to our results the current definition seems inadequate as up to a third of patients had higher grade or cancer outside the prostate.

show abstract

Section: Commentsmentioning

confidence: 70%

Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…18 In the present study, we have identified 8 cases of “non-cancer” based on a single-negative biopsy result (i.e. 16% of the “non-cancer” group).…”

Section: Discussionmentioning

confidence: 86%

A Duplex Quantitative Polymerase Chain Reaction Assay Based on Quantification of α-Methylacyl-CoA Racemase Transcripts and Prostate Cancer Antigen 3 in Urine Sediments Improved Diagnostic Accuracy for Prostate Cancer

et al. 2009

View full text Add to dashboard Cite

Purpose Most men with elevated serum prostate-specific antigen (PSA) levels and negative biopsies require repeat biopsy because of the lack of a sensitive and specific prostate cancer (CaP) detection test. This study evaluated the diagnostic potential of a duplex assay for CaP by quantifying transcript levels of α-methylacyl-CoA racemase (AMACR) and prostate-cancer antigen 3 (PCA3) in urine sediments following prostatic message. Materials and Methods Urine sediments from 92 patients, 43 with 49 without CaP were collected after digital rectal examination. Transcript levels of AMACR, PCA3, and PSA in total RNA isolated from these samples were determined by absolute qRT-PCR. AMACR and PCA3 scores were obtained by normalizing the transcript level to that of PSA for each sample and multiplying by 100. Results AMACR (p=0.006) and PCA3 (p=0.014) scores, but not serum PSA (p=0.306), discriminated specimens from patients with and without CaP, Receiver-operating-characteristic analysis established the diagnostic cutoff scores for the AMACR and PCA3 tests at 10.7 and 19.9, respectively. As determined from these cutoff scores, the AMACR test has 70% (95% CI, 56-83%) sensitivity and 71% (95% CI, 59-84%) specificity, whereas the PCA3 test has 72% (95% CI, 59-85%) sensitivity and 59% (95% CI, 45-73%) specificity for CaP detection. The combined use of AMACR and PCA3 scores in a dual-marker test increased sensitivity to 81% (95% CI, 70-93%) and specificity to 84% (95% CI, 73-94%). Conclusions Urinary AMACR and PCA3 tests were both superior to serum PSA test for detecting CaP. Their combined use in a dual-marker test further improved sensitivity and accuracy and could be used as a surveillance test after repeat negative prostate biopsies.

show abstract

“…In the past decades, the 6-core sextant prostate biopsy scheme, introduced by Hodge et al [10], has been the mainstay for the detection of PC. However, recent studies showed that the sextant biopsy scheme is inadequate [11,12]. Nowadays, 10- or 12-core biopsy is advised, but sampling more than 12 cores does not provide more benefits [13,14,15].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of Different Systematic Prostate Biopsy Methods in the Detection of Prostate Cancer with Ultrasonographic Hypoechoic Lesions - A Comparative Study

Yao²,

Wu³

et al. 2015

Urol Int

View full text Add to dashboard Cite

Objective: To assess if a less extended biopsy in the transperineal approach is sufficient for detection of prostate cancer (PC) in patients with hypoechoic lesions. Methods: This was a prospective study of 167 consecutive patients with prostate hypoechoic lesion and who underwent transperineal ultrasound (TPUS)-guided 12-core and hypoechoic lesion core biopsy between January 2012 and February 2013. Results: PC was detected in 64.1% (107/167) of patients. The PC detection rate of the 12-core prostate biopsy scheme was the highest, but when including the hypoechoic lesion core, there was no difference between the 6- and 12-core schemes (all p > 0.05), irrespective of prostate volume or prostate-specific antigen levels (all p > 0.05). Conclusions: A more limited biopsy scheme could be sufficient for the detection of PC if the hypoechoic lesion is sampled.

show abstract

The role of extended prostate biopsy on prostate cancer detection rate: a study performed on the bench

Cited by 13 publications

References 31 publications

Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy

Undergrading and understaging in patients with clinically insignificant prostate cancer who underwent radical prostatectomy

A Duplex Quantitative Polymerase Chain Reaction Assay Based on Quantification of α-Methylacyl-CoA Racemase Transcripts and Prostate Cancer Antigen 3 in Urine Sediments Improved Diagnostic Accuracy for Prostate Cancer

Diagnostic Value of Different Systematic Prostate Biopsy Methods in the Detection of Prostate Cancer with Ultrasonographic Hypoechoic Lesions - A Comparative Study

Contact Info

Product

Resources

About